Accelerated tumorigenesis in a colorectal cancer model in Siglec-E knockout mice

Brandon Lee Maniaci, D. J. Friedman, S. Crotts, Matthew J. Rajcula, Brady Hammer, Elissa Mai, V. Shapiro
{"title":"Accelerated tumorigenesis in a colorectal cancer model in Siglec-E knockout mice","authors":"Brandon Lee Maniaci, D. J. Friedman, S. Crotts, Matthew J. Rajcula, Brady Hammer, Elissa Mai, V. Shapiro","doi":"10.4049/jimmunol.210.supp.88.12","DOIUrl":null,"url":null,"abstract":"\n The lifetime risk for colorectal cancer in the United States is approximately 4%. Individuals with Inflammatory Bowel Disease, including Ulcerative Colitis and Crohn’s Disease, have a substantially increased risk of developing colorectal cancer. The mechanisms for accelerated tumorigenesis due to enhanced inflammation are not fully characterized. Siglecs (sialic acid immunoglobulin lectin-like proteins) are a family of inhibitory receptors that are negative regulators of the immune response. Siglec-E is an inhibitory receptor that is expressed by innate immune cells, including monocytes, macrophages, neutrophils and dendritic cells. Interestingly, mice deficient in Siglec-E have accelerated development of tumors and reduced survival in a spontaneous mouse model of colorectal cancer (TS4-cre LSL-KRas G12DAPClox 468/wt). While tumors develop at approximately six months in mice with Siglec-E, tumors develop at approximately two months in Siglec-E knockout mice. Initial results indicate that Siglec-E knockout mice also have accelerated gut inflammation using the DSS colitis model as compared to WT mice. Current studies are examining inflammation that develops during tumorigenesis in Siglec-E knockout mice.\n Center for Biomedical Discovery NIH R01 CA243545-01A1 to VSS Mayo Clinic Graduate School of Biomedical Sciences Deans fellowship: Initiative for maximizing student development (IMSD) R25 GM055252-26 Doyon Foundation","PeriodicalId":22698,"journal":{"name":"The Journal of Immunology","volume":"59 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4049/jimmunol.210.supp.88.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The lifetime risk for colorectal cancer in the United States is approximately 4%. Individuals with Inflammatory Bowel Disease, including Ulcerative Colitis and Crohn’s Disease, have a substantially increased risk of developing colorectal cancer. The mechanisms for accelerated tumorigenesis due to enhanced inflammation are not fully characterized. Siglecs (sialic acid immunoglobulin lectin-like proteins) are a family of inhibitory receptors that are negative regulators of the immune response. Siglec-E is an inhibitory receptor that is expressed by innate immune cells, including monocytes, macrophages, neutrophils and dendritic cells. Interestingly, mice deficient in Siglec-E have accelerated development of tumors and reduced survival in a spontaneous mouse model of colorectal cancer (TS4-cre LSL-KRas G12DAPClox 468/wt). While tumors develop at approximately six months in mice with Siglec-E, tumors develop at approximately two months in Siglec-E knockout mice. Initial results indicate that Siglec-E knockout mice also have accelerated gut inflammation using the DSS colitis model as compared to WT mice. Current studies are examining inflammation that develops during tumorigenesis in Siglec-E knockout mice. Center for Biomedical Discovery NIH R01 CA243545-01A1 to VSS Mayo Clinic Graduate School of Biomedical Sciences Deans fellowship: Initiative for maximizing student development (IMSD) R25 GM055252-26 Doyon Foundation
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
siglece基因敲除小鼠结肠直肠癌模型中的加速肿瘤发生
在美国,结直肠癌的终生风险约为4%。患有炎症性肠病的人,包括溃疡性结肠炎和克罗恩病,患结肠直肠癌的风险大大增加。由于炎症增强而加速肿瘤发生的机制尚未完全确定。Siglecs(唾液酸免疫球蛋白凝集素样蛋白)是一类抑制受体,是免疫反应的负调节因子。siglece是一种抑制受体,由先天免疫细胞表达,包括单核细胞、巨噬细胞、中性粒细胞和树突状细胞。有趣的是,在自发性结直肠癌小鼠模型(TS4-cre LSL-KRas G12DAPClox 468/wt)中,siglece缺失的小鼠加速了肿瘤的发展,降低了生存率。在siglece基因敲除小鼠中,肿瘤大约在6个月后发展,而在siglece基因敲除小鼠中,肿瘤大约在2个月后发展。初步结果表明,与WT小鼠相比,siglece敲除小鼠在DSS结肠炎模型中也加速了肠道炎症。目前的研究正在检查siglece基因敲除小鼠肿瘤发生过程中发生的炎症。生物医学发现中心NIH R01 CA243545-01A1到VSS梅奥诊所生物医学科学研究生院院长奖学金:最大化学生发展倡议(IMSD) R25 GM055252-26 Doyon基金会
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Challenges in the Development of NK-92 Cells as an Effective Universal Off-the-Shelf Cellular Therapeutic. Understanding the Role of miR-29a in the Regulation of RAG1, a Gene Associated with the Development of the Immune System. N-Glycan Branching Regulates BTLA Opposite to PD-1 to Limit T Cell Hyperactivity Induced by Branching Deficiency. Immune Response to SARS-CoV-2 in Vaccine-naive Pregnant Women: Assessment of IgG and IgA Antibody Profile at Delivery and 42 Days Postpartum. Top Reads
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1